 Mario Enrico Canonico
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 8 | 2025 | 475 | 2.610 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 279 | 2.220 |
Why?
| | Platelet Aggregation Inhibitors | 15 | 2025 | 463 | 2.060 |
Why?
| | Fibrinolytic Agents | 6 | 2025 | 270 | 1.800 |
Why?
| | Percutaneous Coronary Intervention | 10 | 2025 | 480 | 1.670 |
Why?
| | Heart Failure | 8 | 2025 | 2236 | 1.460 |
Why?
| | Stroke Volume | 7 | 2025 | 612 | 1.210 |
Why?
| | Lower Extremity | 4 | 2024 | 427 | 1.160 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2025 | 54 | 1.140 |
Why?
| | Aspirin | 5 | 2024 | 387 | 1.140 |
Why?
| | Rivaroxaban | 3 | 2024 | 255 | 1.130 |
Why?
| | Factor Xa Inhibitors | 2 | 2024 | 172 | 0.990 |
Why?
| | ST Elevation Myocardial Infarction | 2 | 2022 | 54 | 0.850 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 261 | 0.760 |
Why?
| | Thrombosis | 2 | 2024 | 371 | 0.740 |
Why?
| | Hyperglycemia | 1 | 2025 | 347 | 0.730 |
Why?
| | Anticholesteremic Agents | 1 | 2023 | 153 | 0.720 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 617 | 0.650 |
Why?
| | Venous Thrombosis | 1 | 2022 | 190 | 0.640 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.640 |
Why?
| | Blood Platelets | 3 | 2024 | 408 | 0.630 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2531 | 0.620 |
Why?
| | Mobile Applications | 1 | 2022 | 183 | 0.620 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1291 | 0.610 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 445 | 0.600 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.580 |
Why?
| | Coronavirus Infections | 2 | 2020 | 364 | 0.580 |
Why?
| | Purinergic P2Y Receptor Antagonists | 6 | 2025 | 66 | 0.580 |
Why?
| | Sex Characteristics | 1 | 2023 | 762 | 0.550 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 316 | 0.550 |
Why?
| | Hypertension | 5 | 2025 | 1295 | 0.530 |
Why?
| | Precision Medicine | 1 | 2021 | 429 | 0.530 |
Why?
| | Humans | 46 | 2025 | 137585 | 0.470 |
Why?
| | Blood Glucose | 1 | 2025 | 2186 | 0.470 |
Why?
| | Neoplasms | 4 | 2024 | 2671 | 0.460 |
Why?
| | Adenosine Monophosphate | 3 | 2025 | 66 | 0.440 |
Why?
| | International Classification of Diseases | 2 | 2025 | 135 | 0.440 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1040 | 0.430 |
Why?
| | Platelet Aggregation | 3 | 2024 | 103 | 0.430 |
Why?
| | Coronary Artery Disease | 4 | 2025 | 698 | 0.410 |
Why?
| | Postoperative Complications | 1 | 2024 | 2654 | 0.390 |
Why?
| | Pandemics | 2 | 2020 | 1639 | 0.390 |
Why?
| | Ventricular Function, Left | 4 | 2024 | 534 | 0.370 |
Why?
| | Hemorrhage | 3 | 2025 | 722 | 0.360 |
Why?
| | Anticoagulants | 4 | 2022 | 664 | 0.310 |
Why?
| | Aged | 14 | 2025 | 23961 | 0.310 |
Why?
| | Prevalence | 4 | 2025 | 2734 | 0.310 |
Why?
| | Treatment Outcome | 11 | 2025 | 10811 | 0.300 |
Why?
| | Middle Aged | 14 | 2025 | 33479 | 0.300 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1066 | 0.290 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 382 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.270 |
Why?
| | Male | 20 | 2025 | 67762 | 0.270 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7635 | 0.260 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 388 | 0.260 |
Why?
| | Bumetanide | 1 | 2025 | 5 | 0.240 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2025 | 16 | 0.240 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2025 | 65 | 0.230 |
Why?
| | Hospitalization | 2 | 2025 | 2199 | 0.230 |
Why?
| | Female | 16 | 2025 | 73304 | 0.230 |
Why?
| | Diuretics | 1 | 2025 | 74 | 0.230 |
Why?
| | Coronary Angiography | 4 | 2021 | 317 | 0.220 |
Why?
| | Cardiology | 2 | 2025 | 274 | 0.220 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 310 | 0.220 |
Why?
| | Morphine Derivatives | 1 | 2023 | 17 | 0.220 |
Why?
| | Tablets | 1 | 2023 | 40 | 0.210 |
Why?
| | Secondary Prevention | 1 | 2025 | 233 | 0.210 |
Why?
| | Subtilisin | 1 | 2023 | 4 | 0.210 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.210 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 73 | 0.200 |
Why?
| | Comorbidity | 2 | 2025 | 1622 | 0.200 |
Why?
| | Atrial Remodeling | 1 | 2022 | 9 | 0.190 |
Why?
| | Adenosine | 1 | 2023 | 225 | 0.190 |
Why?
| | Echocardiography | 5 | 2024 | 642 | 0.180 |
Why?
| | Bundle-Branch Block | 1 | 2021 | 31 | 0.180 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 32 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 303 | 0.180 |
Why?
| | Cardiotoxicity | 1 | 2021 | 26 | 0.180 |
Why?
| | Frailty | 1 | 2024 | 170 | 0.180 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 365 | 0.170 |
Why?
| | Drug Compounding | 1 | 2021 | 101 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1477 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2025 | 546 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 415 | 0.170 |
Why?
| | Coronary Stenosis | 1 | 2020 | 38 | 0.170 |
Why?
| | Coronary Occlusion | 1 | 2020 | 19 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 249 | 0.170 |
Why?
| | Radial Artery | 2 | 2021 | 68 | 0.170 |
Why?
| | Blood Pressure | 3 | 2025 | 1786 | 0.170 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 81 | 0.160 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2021 | 141 | 0.160 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 63 | 0.160 |
Why?
| | Myocarditis | 1 | 2021 | 100 | 0.160 |
Why?
| | Smoking Cessation | 1 | 2024 | 442 | 0.160 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 494 | 0.160 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 93 | 0.160 |
Why?
| | Double-Blind Method | 1 | 2024 | 1993 | 0.160 |
Why?
| | Heart Arrest | 1 | 2023 | 339 | 0.150 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5472 | 0.150 |
Why?
| | Italy | 3 | 2025 | 110 | 0.150 |
Why?
| | Chronic Disease | 1 | 2025 | 1793 | 0.150 |
Why?
| | United States | 3 | 2025 | 14841 | 0.150 |
Why?
| | Hepatitis C, Chronic | 1 | 2020 | 164 | 0.150 |
Why?
| | Students, Medical | 1 | 2023 | 348 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2020 | 226 | 0.140 |
Why?
| | Cardiomyopathies | 1 | 2021 | 350 | 0.140 |
Why?
| | Risk Factors | 4 | 2025 | 10388 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2025 | 15657 | 0.130 |
Why?
| | Biomarkers | 2 | 2025 | 4149 | 0.130 |
Why?
| | Telemedicine | 1 | 2025 | 862 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1430 | 0.120 |
Why?
| | Colorado | 1 | 2025 | 4565 | 0.120 |
Why?
| | Femoral Artery | 1 | 2016 | 179 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2020 | 788 | 0.110 |
Why?
| | Registries | 4 | 2025 | 2035 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 530 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2129 | 0.100 |
Why?
| | Administration, Oral | 2 | 2021 | 816 | 0.070 |
Why?
| | Prognosis | 3 | 2021 | 4030 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2111 | 0.070 |
Why?
| | Naphthyridines | 1 | 2025 | 19 | 0.060 |
Why?
| | Nasal Sprays | 1 | 2025 | 5 | 0.060 |
Why?
| | Spironolactone | 1 | 2025 | 36 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2025 | 90 | 0.060 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2024 | 6 | 0.060 |
Why?
| | Biological Availability | 1 | 2025 | 148 | 0.060 |
Why?
| | Platelet Function Tests | 1 | 2024 | 27 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2025 | 91 | 0.060 |
Why?
| | Adult | 3 | 2022 | 37929 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3457 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2024 | 786 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2024 | 564 | 0.050 |
Why?
| | Prasugrel Hydrochloride | 1 | 2022 | 22 | 0.050 |
Why?
| | Emergencies | 1 | 2023 | 164 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 99 | 0.050 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2021 | 60 | 0.040 |
Why?
| | Gadolinium | 1 | 2021 | 82 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 7604 | 0.040 |
Why?
| | Vitamin K | 1 | 2021 | 45 | 0.040 |
Why?
| | Heart Atria | 1 | 2022 | 137 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2025 | 443 | 0.040 |
Why?
| | Disease Management | 1 | 2024 | 628 | 0.040 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2020 | 131 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 248 | 0.040 |
Why?
| | Hepacivirus | 1 | 2020 | 261 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 467 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 1007 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2022 | 706 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 238 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3295 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2057 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2031 | 0.030 |
Why?
| | Stents | 1 | 2020 | 527 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2074 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6828 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2828 | 0.030 |
Why?
| | Quality of Life | 1 | 2025 | 2892 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2804 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 591 | 0.030 |
Why?
| | Body Mass Index | 1 | 2022 | 2389 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 314 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5742 | 0.020 |
Why?
| | Length of Stay | 1 | 2016 | 1215 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1910 | 0.020 |
Why?
| | Animals | 1 | 2021 | 36940 | 0.010 |
Why?
|
|
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|